Thinking of joining a study?

Register your interest

Become a volunteer?

NCT03728673 | RECRUITING | Glioma of Brain

A Study Utilizing Escitalopram in Glioma Patients
Sponsor:

University of Nebraska

Brief Summary:

This pilot study will include grade IV glioma patients treated with SSRIs during approximately a 17 week study period. Changes in cognition and evaluation of psychosocial factors from baseline to after 17 weeks of treatment with SSRI study drug will be calculated.

Condition or disease

Glioma of Brain

Glioma

Intervention/treatment

Escitalopram Oral Capsules

Phase

PHASE2

Detailed Description:

As many as 85% of glioma patients experience cognitive impairment. This is not only from direct tumor involvement, but also worsens with therapy such as cranial radiation and chemotherapy, which further degrade neuronal function. Commonly, impairments in visuospatial skills and executive function are seen. There is evidence that serotonin selective reuptake inhibitors (SSRIs) such as escitalopram improve modulation and function of resting state networks, contribute to neuroplastic changes in brain regions subserving these abilities, and provide general functional support to neuronal cells. In addition to either improving cognition or preventing cognitive decline, treatment with an SSRI may also improve outcomes critical to overall survival in this vulnerable population, including functional independence, psychosocial stability, and quality of life. We hypothesize that following treatment with escitalopram patients will experience improved cognitive and mood function over time. We will also correlate changes in mood structural MRI and electrophysiological correlates of visual pathway function. The addition of escitalopram has the potential to enhance cognitive function and hence functional independence thereby improving quality of life in these patients.

Study Type : INTERVENTIONAL
Estimated Enrollment : 20 participants
Masking : NONE
Primary Purpose : TREATMENT
Official Title : A Pilot Study Utilizing Escitalopram to Address Cognitive Dysfunction in Glioma Patients
Actual Study Start Date : 2019-03-06
Estimated Primary Completion Date : 2026-12
Estimated Study Completion Date : 2027-08

Information not available for Arms and Intervention/treatment

Ages Eligible for Study: 19 Years
Sexes Eligible for Study: ALL
Accepts Healthy Volunteers:
Criteria
Inclusion Criteria
  • * Patient with pathologically proven diagnosis of Grade IV glioma
  • * Patients planning to receive chemotherapy and/or radiation for newly diagnosed disease
  • * Performance status ECOG 0-2 or equivalent
  • * Patients must be age ≥19 years
  • * Life expectancy greater than 6 months
  • * Written informed consent to participate in the study.
Exclusion Criteria
  • * Hemifield defects (as this obscures visual field necessary to participate in all tests)
  • * Inability to undergo MRI
  • * Severe renal impairment defined as GFR\<30 mL/minute
  • * Screen positive for depression or anxiety
  • * Already taking an anti-depressant (SSRI or NSRI)
  • * Have problems tolerating past treatment with SSRI or NSRIs
  • * Females of childbearing potential must have a negative urine pregnancy test at the study enrollment.
  • * Female patients must be either postmenopausal, free from menses for ≥2 years, surgically sterilized, or willing to use two adequate barrier forms of contraception
A Study Utilizing Escitalopram in Glioma Patients

Location Details

NCT03728673

Please Choose a site

How to Participate

Want to participate in this study, select a site at your convenience, send yourself email to get contact details and prescreening steps.

Locations

RECRUITING

United States, Nebraska

University of Nebraska Medical Center

Omaha, Nebraska, United States, 68198